Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania

African Health Sciences

Volumn 11, Issue 2, 2011, Pages 142-150

  Malisa, A ^a,c   Pearce, R ^b   Abdullah, S ^c   Mutayoba, B ^a   Mshinda, H ^c   Kachur, P ^d   Bloland, P ^d   Roper, C ^b  

^a SOKOINE UNIVERSITY OF AGRICULTURE   (Tanzania)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IFAKARA HEALTH INSTITUTE   (Tanzania)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Plasmodium falciparum infection; Polymerase Chain Reaction; Sequence Specific Oligonucleotide Probing; Sulfadoxine Pyrimethamine resistance

Indexed keywords

CHLOROQUINE; PYRIMETHAMINE; SULFADOXINE;

ADULT; ALLELE; ARTICLE; CHILD; CONTROLLED STUDY; DHFR GENE; DHPS GENE; FEMALE; GENE; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; TANZANIA;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENETIC VARIATION; HAPLOTYPES; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PYRIMETHAMINE; SEQUENCE ANALYSIS, DNA; SULFADOXINE; TANZANIA; TETRAHYDROFOLATE DEHYDROGENASE; YOUNG ADULT;

EID: 79961000894     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Le Sueur D, Binka F, Lengeler C, de Savigny D, SnowRW, Teuscher T, Toure Y. An atlas of malaria in Africa. Africa Health Cambridge, UK, FSG Medi Media Ltd. 1998:23-24.
2. Roper C, Pearce R, Bredenkamp B, Gumede J, Drakeley C, Mosha F, et al. Antifolate antimalarial resistance in southeast Africa: A population-based analysis. Lancet 2003; 361: 1174-1181.
3. Roper C, Pearce R, Nair S, Sharp B' Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004 (Wash DC); 305: 1124.
4. Pearce R, Malisa A, Kachur SP, Barnes K, Sharp B, Roper C. Reduced Variation Around Drug Resistant dhfr Alleles in African Plasmodium falciparum. Molecular Biology and Evolution 2005; 22: 1834-1844.
5. Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, et al. Defining the origin of Plasmodium falciparum resistant dhr isolates in Senegal. Acta Tropica 2006; 99: 106-111.
6. McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, et al. Antifolate Resistance in Plasmodium falciparum: Multiple Origins and Identification of Novel dhfr Alleles. Journal of Infectious Diseases 2006; 194: 189-197.
7. Maiga O, Djimde AA, Hubert V, Renard E, Abouy A, Kironde F, et al. A shared Asian Origin of the Triple-Mutant dhfr Allele in Plasmodium falciparum from sites across Africa. Journal of Infectious Diseases 2007; 196: 165-172.
8. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, et al. Emergence of a dhfr Mutation Conferring High-Level Drug Resistance in Plasmodiumfalciparum Populations from Southwest Uganda. Journal of Infectious Diseases 2008; 197: 1598-1604.
9. Certain LK, Briceno M, Kiara SM, Nzila AM, Watkins WM, Sibley CH. Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987-2006. Journal of Infectious Diseases 2008; 197: 1743-51.
10. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A, et al. Therapeutic Efficacy of Sulfadoxine-pyrimethamine and Prevalence of Resistance Markers in Tanzania Prior to Revision of Malaria Treatment Policy: Plasmodium falciparum Dihydrofolate Reductase and Dihydropteroate Synthase Mutations in Monitoring in vivo Resistance. Am J Trop Med Hyg 2004; 71(6): 696-702.
11. Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, et al. Efficacy of Sulfadoxine-Pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy. Malaria Journal 2005; 4:55.
12. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemiacontrol at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357:1471-1477.
13. Menendez C, Schellenberg D, Macete E, Aide P, Kahigwa E, Sanz S, et al. Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. Malar J 2007; 6:132.
14. Gosling RD, Ghani AC, Deen JL, Seidlein L, Greenwood BM, Chandramohan D. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malaria J. 2008; 7:54
15. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of Chloroquine Antimalarial Efficacy in Malawi. N Engl J Med 2006; 355 (19):1959-66.
16. Pearce R, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular Determination of Point Mutation Haplotypes in the Dihydrofolate Reductase and Dihydropteroate Synthase of Plasmodium falciparum in Three Districts of Northern Tanzania. Antimicrobial Agents and Chemotherapy 2003; 47: 1347-1354.
17. Conway DJ, Roper C, Oduola AM, Arnot DE, Kremsner PG, Grobusch MP, et al. High recombination rate in natural populations of Plasmodium falciparum. Proc Natl Acad Sci U S A 1999; 96: 4506-11.
18. Schneider S, Roessli D, Excoffier L. (2000). Arlequin ver. 2.000: software for population genetics data analysis version 2.000 edition. Genetics and Biometry Laboratory, University of Geneva, Geneva, Switzerland.
19. Bwijo B, Kaneko A, Takechi M, Zungu IL, Moriyama Y, Lum JK, et al. High prevalence of quintuple mutant dhfr/dhps genes in Plasmodium infections seven years after introduction of sufadoxine and pyrimethamine as first line treatment in Malawi. Acta Tropica 2003; 85: 363-373.
20. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrobial Agents and Chemotherapy 2000; 44(4): 991-996.
21. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans Roy Soc Trop Med Hyg 2001; 95: 315-319.
22. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg 2003; 69(3): 247-252.